Jefferies Names Top Tobacco Stocks Amid Nicotine Pouch Competition By Investing.com

Velo drove category momentum with volume and value growth of 197.2% and 247.2% in March, adding 14.1m units and accounting for 88.4% of volume growth. ZYN slowed to 2.4% volume growth in March (from 7.1% in Feb) while holding premium pricing at $6.80/unit; on! volumes fell 15.5% and value fell 5.2% while price recovered to $4.60 (vs 52-week avg $3.00). Zone improved sequentially (volume +31.3%, value +39.9%) but Jefferies sees limited upside for it as a US challenger.

Analysis

Momentum in nicotine pouches is amplifying structural advantages for the market leader who controls retail shelf space, distribution agreements and premium pricing perception; that creates a winner-take-most dynamic where incremental volume disproportionately accrues to the retailer-favored brands while smaller challengers struggle to finance costly category entry (slotting fees, PMTA filings, trade promotion). Manufacturing and packaging capacity is the overlooked bottleneck — pouch converters, white-label co-packers and nicotine ingredient suppliers will see lumpy lead times and pricing power over the next 3–9 months, slowing the pace at which challengers can scale even if demand holds.

Regulatory and fiscal risk dominates the path to value: an adverse FDA action, a surprise excise tax, or a state-level flavor/placement restriction can remove option value from the premium players within 60–180 days and hit multiples more than raw volumes. Conversely, a smooth authorization runway plus continued premium-price realization can expand EBITDA margins by high-single to low-double percentage points over 12–24 months as promotional intensity subsides and scale benefits kick in.

From a capital markets standpoint, the market is underweight the asymmetric upside of share consolidation and M&A in this category — acquirers with deep retail relationships can buy share cheaply versus building it organically. The principal downside is a fast, promotional price war or regulatory clampdown; both scenarios are hedgeable with well-timed option structures that limit cash exposure while preserving upside from concentration of retail power.

Key Decisions for Investors

• Pair trade (6–12 months): Long BTI equity (15–25% of position target) / Short MO equity (15–25%). Rationale: BTI captures retail share and pricing premium; MO faces execution and share-loss risk. Target asymmetric payoff: +25–40% upside on BTI vs 20–30% downside protection on the pair if MO rallies. Use equal notional sizing to neutralize tobacco-sector beta.
• Options hedge for PM (3–12 months): Buy PM 9–12 month 1x2 call spread (long near-the-money call, short twice the number of higher-strike calls) sized at 5% portfolio allocation. This keeps defined downside with leveraged upside if PM re-rates on premiumization; breakeven requires a mid-teens % stock move, offering ~2:1 reward-to-risk if category momentum continues.
• BTI directional with limited downside (3–9 months): Buy BTI 6–12 month call spread to capture continued retail share gains; enter on ≤5% intraday pullback or on volume-confirmed breakout. Risk: capped upside but low cost and protected against short-term regulatory headlines.
• Short MO outright or buy puts (3–6 months) as a tactical hedge against promotional spiral or execution miss. Size conservatively (5–10% of a tobacco exposure sleeve) and set stop if MO closes above short-term resistance or if on! messaging shows concrete premiumization traction in national retail rollouts.
• Tactical monitoring alert: If FDA authorizes a major oral-nicotine PMTA or issues guidance favoring premium smoke-free products, rotate 20–30% of short exposure into PM and BTI within 1–3 trading days to capture re-rating; conversely, if FDA issues restrictive guidance, increase put protection and tighten stops within 48 hours.